HALO

HALO

HALO

Letters With This Ticker

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Keywords/Themes	Theme Commentary	Pitches	Letter
2024 Q3	Sep 30, 2024	ACATIS Investment	-	8.8%	1193 HK, 6268 JP, BNTX, HALO, NVO, PLTR, REGN, SMCI, SMFT LN, SWKS	Artificial Intelligence, Data centers, Nuclear Energy, Power Infrastructure, semiconductors	The report underscores the exponential growth in artificial intelligence infrastructure, from semiconductor equipment and performance electronics to data centers and power supply, with European industrial champions playing critical enabling roles. Rising computing intensity, multi-billion-euro model training costs and surging electricity demand are driving investment in semiconductors, grid infrastructure and even nuclear energy solutions to power AI workloads. ACATIS positions portfolios toward companies benefiting from AI-driven capital expenditure cycles, particularly in semiconductors, industrial technology and energy infrastructure.	HALO SMCI 6268 JP SWKS NVO 1193 HK BNTX	View
2025 Q2	Aug 2, 2025	Meridian Growth Fund	4.1%	-	ALGN, CARG, CHDN, COO, CW, DKNG, DOCS, EEFT, FSS, GFS, HALO, RBA, SPT, TRMB, ZD	growth, healthcare, industrials, Quality, risk management, small cap, technology	The fund's investment approach is grounded in investing in high-quality businesses with recurring revenue and sustainable competitive advantages. This emphasis on quality businesses with stable revenues and attractive valuations remains the core strategy going forward.	DKNG FSS CW COO HALO ZD COO HALO ZD	View
2025 Q2	Jul 22, 2025	Artisan Partners Small Cap Fund	7.3%	-3.6%	BIRK, BWXT, CWAN, FLEX, FRSH, HALO, IOVA, IRTC, LSCC, MDGL, MTSI, SAIA, STVN, TTAN, WING	cash flow, fundamentals, Quality, small caps, Valuation discipline	The letter highlights a challenging environment where speculative stocks outperformed quality businesses. Management remains committed to owning high-quality small-cap companies with strong cash flows and attractive valuations. The outlook favors long-term compounding as fundamentals reassert leadership.	GWRE STVN SVTA BIRK MDGL WING BWXT CWAN IRTC MTSI FLEX	View
2024 Q1	May 3, 2024	Laughing Water Capital	2.5%	11.1%	CDMO, CTLT, HALO, LFCR, NN, NVDA, PAR, TACT, THRY	Biotechnology, Capacity, CDMO, long-term, Manufacturing, small caps, value	Large portion of portfolio invested in Contract Drug Manufacturing Organizations focused on biologics. Both Lifecore and Avid positioned to benefit from industry consolidation as Catalent is acquired by Novo Holdings and Chinese CDMOs face regulatory restrictions. Companies have available capacity during industry shortage and should benefit from tremendous operating leverage as capacity fills.		View
2024 Q1	Apr 15, 2024	Artisan Partners Small Cap Fund	9.0%	14.0%	ARGX, ASND, BL, CCCS, ELF, ETSY, FIVE, FND, FRPT, HALO, IPGP, LSCC, MPWR, MYRG, PCOR, SAIA, SHLS, SMAR, TREX, VMI, WING	AI, Biotechnology, Energy Transition, growth, healthcare, semiconductors, small cap, software	Healthcare biotechnology holdings faced R&D setbacks despite solid commercial progress. Argenx's Vyvgart failed two additional indications in Q4, Halozyme experienced underperformance related to Argenx setbacks, and Ascendis faced FDA manufacturing questions for TransCon PTH. The team maintains conviction in de-risked biotech assets with proven drugs and diversified pipelines.		View
2025 Q1	Mar 31, 2025	Artisan Partners Small Cap Fund	-10.1%	-10.1%	ALAB, ARIS, ASCB, BFAM, BROS, FRSH, FTAI, GWRE, HALO, INTA, IRTC, KTOS, MOD, MTSI, MYRG, PEN, SG, SN, TWST, VCYT	AI, Biotechnology, Cloud, defense, growth, healthcare, small caps, Trade Policy	The introduction of China's DeepSeek AI model challenged market assumptions around AI infrastructure spending durability. This development raised questions about US leadership in AI and long-term returns on AI investments, particularly impacting data center capacity enablers in the portfolio.		View
2025 Q1	Mar 31, 2025	Meridian Growth Fund	-8.0%	-8.0%	ALIT, CARG, CHDN, COO, EEFT, HALO, OKTA, RBA, STE, TNDM, TRMB, WAY, ZD	Biotechnology, cybersecurity, growth, healthcare, Quality, Resilience, small caps, tariffs	The fund focuses on small-cap growth investing through the Russell 2500 Growth Index benchmark, with emphasis on high-quality businesses with recurring revenue and sustainable competitive advantages. The strategy demonstrated resilience during the quarter's market decline, outperforming on six of seven days when the index declined 2% or more.	CARG TNDM ZD RBA HALO OKTA	View
2025 Q1	Mar 31, 2025	AMG GW&K Small Cap Core Fund	-7.3%	-7.3%	ADC, ARQT, BWIN, CBZ, CHX, COCO, FLYW, FNA, GBCI, GMED, HALO, HLI, HMN, ICFI, INSM, INTA, ITCI, LOPE, MGY, MTSI, NWE, PAR, PATK, PPBI, PRIM, RBC, SKY, SPXC, STAG, STRL, SWTX, TNDM, UMBF, UTZ	AI, Biotechnology, energy, financials, Quality, small caps, Trade Policy	The fund discusses navigating uncertainty from tariff announcements and trade policy changes by the current U.S. Administration. The manager analyzes potential impacts on manufacturing, consumers, and trading partners, while monitoring for signs of policy moderation or negotiation.		View
2024 Q1	Mar 31, 2024	Baird Small/Mid Cap Growth Equity Fund	1.9%	1.9%	BOOT, BROS, BSY, BWXT, CELH, CHDN, CNMD, CWAN, DAVA, DECK, DT, EXAS, FIVE, FOUR, GLBE, GLOB, GXO, HALO, ICLR, INSP, KAI, KNSL, KNX, LFUS, LGIH, LSCC, LW, MNDY, MSTR, MTDR, ONTO, PCOR, PEN, PODD, QDEL, RGEN, SAM, SITM, SMCI, SMPL, SWAV, TARS, TECH, TREX, VITA, WNS, WSO, XPEL	AI, growth, healthcare, Performance, semiconductors, small cap, technology	AI spending expectations drove significant outperformance in technology stocks, particularly benefiting companies like Super Micro Computer which investors view as the next Nvidia. The fund has limited direct AI exposure through Lattice Semiconductor and has not reached comfort levels on sustainable AI impact for many benchmark holdings. AI headwinds affected both technology and industrial sectors as datacenter and semiconductor manufacturing equipment companies saw outsized gains.		View
2024 Q4	Dec 31, 2024	Artisan Partners Small Cap Fund	0.6%	14.7%	ABMD.CO, ALAB, COCO, CROX, FLS, GTLB, HALO, INSM, ITGR, JBT, LSCC, MTSI, NOVT, ONTO, PSN, RGEN, SDHC, SN, STVN, VCYT, VSEC	AI, Biotechnology, energy, healthcare, semiconductors, small cap, technology	Data centers are energy-intensive and with AI expansion, energy consumption is projected to grow exponentially. Portfolio companies like Astera Labs and MACOM are benefiting from growing AI datacenter spending. Cloud software franchises are making steady progress introducing AI functionality into their leading solution suites.		View
2023 Q4	Dec 31, 2023	Artisan Partners Small Cap Fund	9.0%	14.0%	ARGX, ASND, CCCS, DUOL, ETSY, EXAS, FIVE, FND, HALO, IRTC, LSCC, MPWR, PCOR, RGEN, SAIA, SMAR, SWAV, TREX, VMI, WING	Biotechnology, Energy Transition, growth, healthcare, semiconductors, small cap, software, technology	Healthcare biotechnology holdings faced R&D setbacks despite solid commercial progress. Argenx's Vyvgart trials for two additional indications failed, Halozyme experienced underperformance related to Argenx setbacks, and Ascendis faced FDA manufacturing questions for TransCon PTH approval.		View
2023 Q4	Dec 31, 2023	Baird Small/Mid Cap Growth Equity Fund	7.8%	10.9%	BJ, BOOT, BSY, BWXT, COCO, CWAN, DAVA, DECK, DSGX, DT, EXLS, FIVE, FND, FOUR, GLOB, GNRC, GTLS, HALO, IEX, INSP, KAI, KNSL, LGIH, LSCC, LW, MTZ, NEO, NSA, PCTY, PODD, POOL, PTC, PWSC, RBC, RVNC, SAM, SWAV, TREX, TTC, TYL, WNS, WSO	financials, growth, healthcare, industrials, rates, small cap, technology	Lower-than-expected inflation report in late October led markets to declare an end to Fed tightening and begin discounting multiple rate cuts in 2024. Interest-rate-sensitive stocks rallied sharply late in the quarter, benefiting housing-related and financial stocks. The changed outlook on rates drove significant market movements throughout the quarter.		View
2025 Q3	Oct 24, 2025	Meridian Growth Fund	-1.8%	-	ALGN, ALIT, ALKT, CARG, CHDN, COO, DT, GFS, HALO, MDGL, RELY, SPT, STE, TRMB, ZD	AI, growth, healthcare, industrials, Quality, small caps, SMID, technology	The fund sees signs of exuberance and speculative behavior in AI infrastructure ecosystem, particularly in technology and industrial sectors. While AI remains transformative long-term, valuations have become disconnected from fundamentals with companies exceeding $10 billion market caps lacking profits or revenues. The fund remains disciplined and unlikely to pursue high-momentum AI names without meaningful revenues or profitability.	ZD HALO MDGL ALGN SPT ALIT	View
2023 Q3	Sep 30, 2023	Artisan Mid Cap Fund	2.4%	6.6%	ARGX, ASND, BNTX, DXCM, EXAS, GPN, HALO, HUBS, IR, JBL, LSCC, PWR, RPGN, SAIA, SWAV, TEAM, VEEV, WING, WST, ZS	AI, Biotechnology, Energy Transition, growth, healthcare, mid cap, semiconductors, technology	Manager is bullish on GLP-1 obesity therapies, especially the growth they should enable for biologics packaging franchises like West Pharmaceutical. Believes the public health benefits are real but unlikely to materially restrain growth opportunities of medical device holdings for many years. Taking advantage of attractive valuations in adversely impacted holdings like DexCom.		View
2023 Q3	Sep 30, 2023	Artisan Partners Small Cap Fund	9.0%	14.0%	ARGX, ASND, BL, BSY, CAVA, CCCS, ETSY, EXAS, FIVE, GLBE, GWRE, HALO, IRTC, LSCC, MTSI, PCOR, PZZA, RGEN, SAIA, SMAR, SPXC, STVN, SWAV, TREX, WCC, WING, WMS	Biotechnology, growth, healthcare, Medical Devices, semiconductors, small cap, software, technology	Manager discusses the rapid growth of GLP-1 obesity drugs from Novo Nordisk and Eli Lilly, noting their impact on medical device stocks. While acknowledging public health benefits, believes the effects on cardiovascular disease incidence will take time and that opportunities for innovative franchises to gain share outweigh market expansion concerns.		View
2024 Q2	Jul 17, 2022	Laughing Water Capital	2.5%	11.1%	APG, CDMO, CTLP, ERIC, HALO, HGV, LFCR, LMB, NN, THRY, VTY.L, XPOF	Biotechnology, contrarian, Franchising, momentum, quantitative, small caps, value	Manager focuses on contrarian investing in businesses trading at single digit multiples of free cash flow, believing good businesses led by incentivized people will not trade at these levels forever. The strategy targets hidden corners of the market with optical, operational, or structural problems that are likely temporary.	XPOF CTLP	View
2023 Q1	Mar 31, 2023	Bernzott Capital Advisors – US Small Cap	8.5%	8.5%	ATSG, BV, GVA, HALO, HCI, HLMN, PTEN, SRCL, TA, TCBI, WSC	Banking, Commercial real estate, Quality, small caps, value	Manager emphasizes commitment to investment philosophy focused on high quality businesses with attractive cash flow and strong balance sheets. Attention to valuation should support investment returns as current interest rate regime inhibits valuation expansion. Small cap valuations look attractive relative to large caps.	PTEN HLMN	View
2022 Q1	Mar 31, 2022	Bernzott Capital Advisors – US Small Cap	8.5%	8.5%	CMP, HALO, HCI, HI, JBI, MP, VNOM	-			View
2022 Q4	Feb 22, 2023	Bernzott Capital Advisors – US Small Cap	8.5%	8.5%	BV, GV, GVA, HALO, HHC, JRVR, KN, MP, QUOT, SP, SSTK, UPLD, VNOM	-			View
2023 Q4	Jan 30, 2024	Bernzott Capital Advisors – US Small Cap	8.5%	8.5%	ADTN, APG, ECPG, GVA, HALO, HCI, JRVR, NNN, PTEN, SP, SRC	energy, financials, infrastructure, Quality, real estate, small caps, value	Small caps led the market rally in Q4 with 14.0% returns, outperforming large caps. Despite the rally, small caps trade at over a 3-turn discount to large caps, which the manager believes should narrow over time. The broadening out of market returns should benefit small caps, as historically when large cap returns broaden, small caps tend to outperform.	NNN COO\|CW\|DKNG\|FSS\|HALO\|ZD PTEN GVA AFM CN\|B4B GR\|BLU SJ\|COH SJ\|HCI\|KO\|KSPI\|MGROS TI\|MTN SJ\|NE\|NPK SJ\|OCE SJ\|PPI\|PRX NA\|SAHOL TI\|SES\|WINE LN	View
2022 Q4	Jan 30, 2023	Carillon Eagle Small Cap Growth Fund	0.0%	0.0%	EVH, GTLS PR B, HALO, LNTH, LSCC, LTHM, MSA, SMPL, SWAV, VNOM	-			View
2024 Q4	Jan 17, 2025	Driehaus Small Cap Growth Fund	1.1%	-34.3%	CALX, HALO, KNSL, PI, WSC	Fed policy, growth, inflation, infrastructure, Onshoring, Recession, small cap, Valuations	Manager believes inflation will continue to fall as key drivers (excess money supply, excess savings, supply chain issues, labor shortages) are normalizing. M2 money supply is now negative year-over-year, excess savings are declining, and supply chains have largely recovered.		View
2023 Q4	Jan 17, 2024	Driehaus Small Cap Growth Fund	6.4%	27.0%	CALX, HALO, KNSL, PI, WSC	Biotechnology, Fed policy, growth, inflation, infrastructure, Onshoring, Recession, small cap	Manager believes inflation will continue to fall as key drivers (excess money supply, excess savings, supply chain issues, labor shortages) are normalizing. M2 money supply is now negative year-over-year, excess savings are declining, and supply chains have largely recovered.		View

Pitches With This Ticker

Date	Pitch Type	Author	Company	Industry	Sub Industry	Bull / Bear	Stock Exchange	Keywords	Action
Apr 13, 2026	Fund Letters	Meridian Growth Fund	Halozyme Therapeutics, Inc.	Health Care	Biotechnology	Bull	NASDAQ	biologics, biotechnology, Drug Delivery Platform, ENHANZE Technology, healthcare innovation, Medicare Pricing, Subcutaneous Delivery	View Pitch
Apr 13, 2026	Fund Letters	Meridian Growth Fund	Halozyme Therapeutics, Inc.	Health Care	Biotechnology	Bull	NASDAQ	biotechnology, drug delivery, EBITDA margins, healthcare, Pharmaceutical, Platform Technology, Subcutaneous	View Pitch
Feb 26, 2026	Fund Letters	Dr. Hendrik Leber	Halozyme Therapeutics, Inc.	Health Care	Biotechnology	Bull	NASDAQ	asset-light, biotechnology, drug delivery, Partnerships, royalties, Subcutaneous Injection	View Pitch
Jan 8, 2026	Fund Letters	Chad Meade	Halozyme Therapeutics Inc.	Health Care	Biotechnology	Bear	NASDAQ	Key Catalysts Include Final CMS Ruling And New ENHANZE-Enabled Drug Launches.	View Pitch
Nov 29, 2025	Fund Letters	Chad Meade	Halozyme Therapeutics, Inc.	Health Care	Biotechnology	Bull	NASDAQ	drug delivery, FCF, guidance, Partners, platform, royalties	View Pitch
Nov 29, 2025	Fund Letters	Chad Meade	Halozyme Therapeutics, Inc.	Health Care	Biotechnology	Bull	NASDAQ	drug delivery, FCF, guidance, Partners, platform, royalties	View Pitch
Aug 8, 2025	Seeking Alpha	Stephen Ayers	Halozyme Therapeutics, Inc.	Health Care	Biotechnology	Neutral	NASDAQ	—	View Pitch

BSD Shareholders of HALO

This report provides a detailed summary of investor holdings for a specified stock ticker, highlighting key metrics such as fund name, total assets under management (AUM), invested value, portfolio weight, and shares owned. It also tracks changes in share ownership during the last quarter, including the percentage of shares bought or sold and the percentage of outstanding shares owned. The data is generated using an API that processes investor holdings and calculates these values for each fund. This report helps investors and analysts monitor the stock positions of major funds, identify investment trends, and assess the influence of large investors on individual stocks.

Filing Date: September 30, 2025

Manager Name	Fund Name	Fund AUM	Invested Value	Portfolio Weight	Shares Owned	Shares Bought / Sold During Quarter	% Bought / Sold During Quarter	% of Shares Outstanding Owned
No investor data available.

Join for free and get access to the buyside

Get insights from the world's most influential hedge fund investors direct to your inbox

Follow Us On: